SK Biopharmaceuticals Partners with Interon to Develop First-in-Class Autism Treatment Using Neuroimmune Approach
核心洞察
SK Biopharmaceuticals (搜索) has signed a joint research agreement with Boston-based Interon Laboratories (搜索) to develop a novel autism spectrum disorder (搜索) treatment through neuroimmune system modulation.
The collaboration focuses on developing IL-17 activator compounds (搜索) that enhance interleukin-17 (搜索) receptor signaling in brain neurons to improve autism symptoms.
This partnership represents SK Biopharmaceuticals (搜索)' strategic expansion beyond epilepsy (搜索) into neuroimmunology as part of its "Next CNS" vision for next-generation central nervous system therapeutics.
SK Biopharmaceuticals (搜索), the pharmaceutical arm of South Korea's SK Group, has entered into a strategic partnership with Boston-based biotech company Interon Laboratories (搜索) to develop a first-in-class treatment for autism spectrum disorder (搜索) (ASD) using an innovative neuroimmune approach. The joint research and development agreement, signed on October 31, marks a significant expansion of SK Biopharmaceuticals' therapeutic focus beyond epilepsy (搜索) into the emerging field of neuroimmunology.
Novel Neuroimmune Mechanism Targets IL-17 Pathway
The collaboration centers on developing novel IL-17 activator compounds (搜索) that work through a unique mechanism of action. The approach involves enhancing the signaling pathway of interleukin-17 (搜索) (IL-17) receptors in brain neurons to improve autism-related symptoms. IL-17, a protein that acts as a signaling molecule in the immune system, is secreted by immune cells and plays a crucial role in the interaction between the nervous and immune systems.
This neuroimmunological approach represents a departure from traditional autism treatments by focusing on strengthening signal transduction of neuronal IL-17 receptors (搜索) rather than targeting neurotransmitter systems directly. The strategy leverages the growing understanding of how immune system modulation can influence central nervous system function and behavior.
Strategic Partnership Combines Complementary Expertise
The partnership brings together SK Biopharmaceuticals (搜索)' proven drug development capabilities with Interon's specialized neuroimmunology expertise. SK Biopharmaceuticals contributes its medicinal chemistry and lead optimization experience, gained through the in-house development of cenobamate, an innovative epilepsy (搜索) drug. Interon provides its proprietary platform technology that enables rapid identification of hit molecules at the early drug discovery stage.
Interon, founded in 2020 by Professor Heo Junryul of Harvard Medical School and Professor Gloria Choi of the Massachusetts Institute of Technology (MIT), focuses specifically on developing small molecule therapeutics for CNS diseases through neuroimmune system modulation. The company's specialized platform technology is designed to accelerate the early stages of drug discovery.
Accelerated Development Timeline Expected
The joint research project is already proceeding with an initial hit molecule secured, which is expected to enhance both the speed of candidate discovery and the probability of success. This head start positions the collaboration to potentially develop a preclinical candidate more rapidly than starting from scratch.
Under the terms of the agreement, if the research proves successful, SK Biopharmaceuticals (搜索) will have exclusive rights to enter into a contract for the resulting compound, providing the company with a clear path to advance any promising candidates through clinical development.
Expansion of Next CNS Strategy
This collaboration represents a pivotal component of SK Biopharmaceuticals (搜索)' "Next CNS" strategy, which encompasses the company's commitment to developing next-generation treatments for central nervous system disorders (搜索). The partnership signifies the company's strategic move to establish neuroimmunology as a new growth pillar alongside its established epilepsy (搜索) franchise.
"This joint research is an important milestone as SK Biopharmaceuticals (搜索) establishes neuroimmunology as a new growth axis and embarks on the development of next-generation CNS therapeutics," said Lee Donghoon, CEO of SK Biopharmaceuticals. "Based on open innovation, we will accelerate our Next CNS strategy and continuously expand our therapeutic areas and pipeline in the global market."
Emerging Therapeutic Paradigm
Neuroimmunology is gaining recognition as a next-generation therapeutic paradigm for central nervous system disorders (搜索), despite its high research complexity. The field is drawing attention as a potential breakthrough approach for developing CNS therapeutics by targeting the intricate interactions between the nervous and immune systems.
The collaboration positions both companies at the forefront of this emerging field, combining SK Biopharmaceuticals (搜索)' established CNS drug development track record with Interon's cutting-edge neuroimmune research capabilities. This open innovation approach reflects the growing trend of pharmaceutical companies partnering with specialized biotechs to access novel therapeutic modalities and accelerate drug discovery timelines.